Portal de Periódicos da CAPES

Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021

2021; Centers for Disease Control and Prevention; Volume: 27; Issue: 11 Linguagem: Inglês

10.3201/eid2711.211886

1080-6059

Aharona Glatman‐Freedman, Yael Hershkovitz, Zalman Kaufman, Rita Dichtiar, Lital Keinan‐Boker, Michal Bromberg,

COVID-19 Clinical Research Studies

In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting.